SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending due to recent upgrades from Deutsche Bank, citing a 'clear growth path' and a Buy rating with a target price of $71. The community is discussing the company's potential to achieve profitability by late 2025, driven by government backing and increasing magnet production. Some investors believe MP is heavily influenced by AI speculative momentum, while others see the recent price action and rare earth reports as creating a buying opportunity.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amid discussions about potential ETF approvals and regulatory clarity, particularly regarding the reopened government. The community is weighing the impact of these developments and the possibility of a breakout, with some cautioning about resistance levels and range-bound trading. Technical indicators and overall market conditions are being closely monitored for clues about XRP's next move.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending amid news of a $100M advertising deal and a potential $150M GPU services agreement with Tether, alongside the acquisition of Northern Data, signaling a shift towards AI and cloud services. The community is buzzing about the potential of these deals to transform Rumble into a major player in the neocloud space. Some are expressing concerns over the timing of the Northern Data news prior to earnings and the impact of these moves on profitability.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending as investors eagerly await the CHMP's opinion on Blarcamesine for Alzheimer's, with the community debating whether the decision will come in November or December. Discussions revolve around the potential for a short squeeze and the impact of a positive opinion on partnership deals, with some expressing frustration over the stock's price action amid regulatory anticipation. The broader context involves comparisons to other Alzheimer's drugs and speculation about the company's strategy following a potential approval.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya is trending as investors anticipate upcoming Q3 earnings, especially in light of broader fintech sector performance and potential impacts from macro events like government shutdowns. Community members are actively discussing the high short interest, possibilities for a short squeeze, and the potential effect of bank earnings and regulatory changes on Pagaya's valuation. Some are drawing comparisons to other fintech companies, while others focus on Pagaya's unique AI-driven approach to credit risk assessment.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

GSAT is trending amid reports that the company is exploring a potential sale, attracting interest from SpaceX and potentially sparking a bidding war. Community members are speculating on potential acquisition prices, with some suggesting figures significantly above the reported $10 billion offer, and analyzing the implications for Apple, a key partner. Discussions also involve the strategic value of Globalstar's spectrum and its role in the evolving satellite communication landscape, especially in relation to potential partnerships or acquisitions.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

PSKY is trending amid speculation about a potential acquisition of Warner Bros. Discovery, with community members debating the likelihood of a deal and its potential impact. Some believe AI integration will be key to the merger's success, while others express concern about debt levels and leadership; despite uncertainty surrounding the merger, many see long-term potential.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid speculation of a potential acquisition by Netflix, adding to existing interest from Paramount and Comcast, which has stimulated community discussion around potential bidding wars and the company's ultimate valuation. Investors are weighing the impact of a potential deal against the possibility of WBD remaining independent, with some focusing on upcoming earnings and the company's debt. The community is actively debating the merits of different acquisition scenarios and potential outcomes for shareholders.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

VIR is trending due to promising early clinical data from its dual-masked T-cell engagers in oncology, sparking community excitement about its potential in solid tumor treatments. Discussions revolve around the efficacy and safety of VIR-5818 and VIR-5500, with some noting similarities to JANX's technology and highlighting VIR's strong cash position. The broader context includes anticipation for upcoming milestones, such as the beginning of phase 3 trials for Hepatitis Delta and Q2 data releases, fueling speculation about partnerships and future growth.

Peabody Energy Corp. engages in the business of coal mining. It operates through the following business segments: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal, and Corporate and Other. The Seaborne Thermal segment consist of mines in New South Wales, Australia. The Seaborne Metallurgical segment includes mines in Queensland, Australia, one in New South Wales, Australia and one in Alabama, USA. The Powder River Basin segment focuses on mines in Wyoming. The Other U.S. Thermal segment reflects on the mining, preparation and sale of thermal coal, sold primarily to electric utilities in the U.S. under long-term contracts, with a relatively small portion sold as international exports as conditions warrant. The Corporate and Other segment involves administrative expenses, results from equity method investments, trading and brokerage activities, minimum charges on certain transportation-related contracts, the closure of inactive mining sites, the impact of foreign currency remeasurement and certain commercial matters. The company was founded by Francis S. Peabody in 1883 and is headquartered in St. Louis, MO.

Peabody Energy Corp. - Ordinary Shares New

BTU is trending as traders discuss potential catalysts including increased energy demand for AI and the possibility of government stakes in coal companies. Community sentiment appears bullish, focusing on long-term potential and recent analyst target price increases. Discussions also include the potential impact of policy changes and Peabody's position in the energy sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nektar Therapeutics (NASDAQ:NKTR) Receives Average Rating of "Moderate Buy" from Analysts

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven brokerages that are covering the firm, MarketBeat.com reports. One research...

Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results, Beats Estimates By $1.00 EPS

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.85) EPS for the quarter, beating the consensus estimate...

New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting New Data from REZOLVE-AD Study of Rezpegaldesleukin...

Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y

NKTR posts a narrower Q3 loss and a revenue beat, while its rezpeg program advances with key phase IIb milestones.

Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of +35.09% and +11.42%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Nektar Therapeutics Reports Third Quarter 2025 Financial Results

Nektar Therapeutics Reports Third Quarter 2025 Financial Results Nektar Therapeutics Reports Third Quarter 2025 Financial Results PR Newswire SAN FRANCISCO, Nov. 6, 2025 SAN FRANCISCO, Nov. 6, 2025...

Guardian Pharmacy Services (GRDN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Guardian Pharmacy (GRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London PR Newswire SAN...

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets Nektar to Announce Financial Results for the Third Quarter on...

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Current Price	$58.15
Prev Close	$55.12
Open	$56.00
Dividend Yield	0.00%
50-Day Moving Average	$54.43
Beta	2.01
Avg. Volume	842,874.74
PE Ratio	-6.42

52-Week High	$66.92
52-Week Low	$6.48
Market Capitalization	$1.06B
EPS (Annual)	-$8.68
Price to Book	-28.80
Revenue Per Employee	$1.61M
Enterprise Value/EBITDA	N/A

NKTR
Nektar Therapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NKTR News

NKTRNektar Therapeutics